Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease-Reference-Cited by-同舟云学术

Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease

Published:1984-11 Issue:5 Volume:4 Page:890-901
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Packer Milton,Medina Norma,Yushak Madeline

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference63 articles.

1. Deleterious effects of hydralazine in patients with pulmonary hypertension;Packer;N Engl J Med,1982

2. Recent studies in primary pulmonary hypertension including pharmacodynamic observations on pulmonary vascular resistance;Dresdale;Bull NY Acad Med,1954

3. Primary pulmonary hypertension treated with oral phentolamine;Ruskin;Ann Intern Med,1979

4. Effects of tolazoline hydrochloride (Priscoline) on circulatory dynamics in patients with pulmonary hypertension;Rudolph;Am Heart J,1958

5. Adverse hemodynamic effects of phentolamine in primary pulmonary hypertension;Cohen;Ann Intern Med,1981

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying risk factors for perioperative decline in right ventricular performance in cardiac surgery patients: a prospective observational study in a tertiary care hospital;BMJ Open;2023-02

2. Clinical evaluation of nebulized verapamil in out‐patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease;The Clinical Respiratory Journal;2022-11-06

3. Perioperative right ventricular function and dysfunction in adult cardiac surgery—focused review (part 2—management of right ventricular failure);Indian Journal of Thoracic and Cardiovascular Surgery;2021-11-04

4. Protein expression profile changes of lung tissue in patients with pulmonary hypertension;PeerJ;2020-01-31

5. Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities;Therapeutic Advances in Chronic Disease;2017-02